Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma

Ie Ming Shih, Kentaro Nakayama, Gang Wu, Naomi Nakayama, Jinghui Zhang, Tian-Li Wang

Research output: Contribution to journalArticle

Abstract

On the basis of digital karyotyping, we have identified a new, discrete amplified region at ch19p13.2 in a high-grade ovarian serous carcinoma. To further characterize this region, we determined the frequency and biological significance of ch19p13.2 amplification by analyzing 341 high-grade serous carcinomas from The Cancer Genome Atlas (TCGA) and found an increased DNA copy number at this locus in 18% of cases. We correlated the DNA and RNA copy number by analyzing the TCGA data set for all amplified genes and detected seven genes within ch19p13.2 that were significantly correlated (R0.54) and were, in fact, listed as the top 100 potential driver genes at a genome-wide scale. Interestingly, one of the seven genes, NACC1, encoding NAC1 was previously reported to be involved in the development of tumor recurrence in ovarian serous carcinoma and to have a causal role in the development of paclitaxel resistance. Therefore, we selected NACC1 for validation in an independent cohort. On the basis of fluorescence in situ hybridization, we found that 35 (20%) of 175 high-grade serous carcinomas had an increased DNA copy number at the NACC1 locus, and those amplified cases were associated with early disease recurrence within 6 months (P0.013). A significantly high level of NAC1 protein expression based on immunohistochemistry was detected in amplified tumors as compared with non-amplified tumors (P0.005). In summary, our data suggest that amplification at the ch19p13.2 NACC1 locus, leading to NAC1 overexpression, is one of the molecular genetic alterations associated with early tumor recurrence in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)638-645
Number of pages8
JournalModern Pathology
Volume24
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Carcinoma
Neoplasms
Atlases
Genome
Recurrence
Genes
DNA
Karyotyping
Paclitaxel
Fluorescence In Situ Hybridization
Ovarian Neoplasms
Molecular Biology
Immunohistochemistry
RNA
Proteins

Keywords

  • gene amplification
  • ovarian cancer
  • serous carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. / Shih, Ie Ming; Nakayama, Kentaro; Wu, Gang; Nakayama, Naomi; Zhang, Jinghui; Wang, Tian-Li.

In: Modern Pathology, Vol. 24, No. 5, 05.2011, p. 638-645.

Research output: Contribution to journalArticle

Shih, Ie Ming ; Nakayama, Kentaro ; Wu, Gang ; Nakayama, Naomi ; Zhang, Jinghui ; Wang, Tian-Li. / Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. In: Modern Pathology. 2011 ; Vol. 24, No. 5. pp. 638-645.
@article{6b7b45ffa5da489cbddf8fac1ebe37a3,
title = "Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma",
abstract = "On the basis of digital karyotyping, we have identified a new, discrete amplified region at ch19p13.2 in a high-grade ovarian serous carcinoma. To further characterize this region, we determined the frequency and biological significance of ch19p13.2 amplification by analyzing 341 high-grade serous carcinomas from The Cancer Genome Atlas (TCGA) and found an increased DNA copy number at this locus in 18{\%} of cases. We correlated the DNA and RNA copy number by analyzing the TCGA data set for all amplified genes and detected seven genes within ch19p13.2 that were significantly correlated (R0.54) and were, in fact, listed as the top 100 potential driver genes at a genome-wide scale. Interestingly, one of the seven genes, NACC1, encoding NAC1 was previously reported to be involved in the development of tumor recurrence in ovarian serous carcinoma and to have a causal role in the development of paclitaxel resistance. Therefore, we selected NACC1 for validation in an independent cohort. On the basis of fluorescence in situ hybridization, we found that 35 (20{\%}) of 175 high-grade serous carcinomas had an increased DNA copy number at the NACC1 locus, and those amplified cases were associated with early disease recurrence within 6 months (P0.013). A significantly high level of NAC1 protein expression based on immunohistochemistry was detected in amplified tumors as compared with non-amplified tumors (P0.005). In summary, our data suggest that amplification at the ch19p13.2 NACC1 locus, leading to NAC1 overexpression, is one of the molecular genetic alterations associated with early tumor recurrence in ovarian cancer.",
keywords = "gene amplification, ovarian cancer, serous carcinoma",
author = "Shih, {Ie Ming} and Kentaro Nakayama and Gang Wu and Naomi Nakayama and Jinghui Zhang and Tian-Li Wang",
year = "2011",
month = "5",
doi = "10.1038/modpathol.2010.230",
language = "English (US)",
volume = "24",
pages = "638--645",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma

AU - Shih, Ie Ming

AU - Nakayama, Kentaro

AU - Wu, Gang

AU - Nakayama, Naomi

AU - Zhang, Jinghui

AU - Wang, Tian-Li

PY - 2011/5

Y1 - 2011/5

N2 - On the basis of digital karyotyping, we have identified a new, discrete amplified region at ch19p13.2 in a high-grade ovarian serous carcinoma. To further characterize this region, we determined the frequency and biological significance of ch19p13.2 amplification by analyzing 341 high-grade serous carcinomas from The Cancer Genome Atlas (TCGA) and found an increased DNA copy number at this locus in 18% of cases. We correlated the DNA and RNA copy number by analyzing the TCGA data set for all amplified genes and detected seven genes within ch19p13.2 that were significantly correlated (R0.54) and were, in fact, listed as the top 100 potential driver genes at a genome-wide scale. Interestingly, one of the seven genes, NACC1, encoding NAC1 was previously reported to be involved in the development of tumor recurrence in ovarian serous carcinoma and to have a causal role in the development of paclitaxel resistance. Therefore, we selected NACC1 for validation in an independent cohort. On the basis of fluorescence in situ hybridization, we found that 35 (20%) of 175 high-grade serous carcinomas had an increased DNA copy number at the NACC1 locus, and those amplified cases were associated with early disease recurrence within 6 months (P0.013). A significantly high level of NAC1 protein expression based on immunohistochemistry was detected in amplified tumors as compared with non-amplified tumors (P0.005). In summary, our data suggest that amplification at the ch19p13.2 NACC1 locus, leading to NAC1 overexpression, is one of the molecular genetic alterations associated with early tumor recurrence in ovarian cancer.

AB - On the basis of digital karyotyping, we have identified a new, discrete amplified region at ch19p13.2 in a high-grade ovarian serous carcinoma. To further characterize this region, we determined the frequency and biological significance of ch19p13.2 amplification by analyzing 341 high-grade serous carcinomas from The Cancer Genome Atlas (TCGA) and found an increased DNA copy number at this locus in 18% of cases. We correlated the DNA and RNA copy number by analyzing the TCGA data set for all amplified genes and detected seven genes within ch19p13.2 that were significantly correlated (R0.54) and were, in fact, listed as the top 100 potential driver genes at a genome-wide scale. Interestingly, one of the seven genes, NACC1, encoding NAC1 was previously reported to be involved in the development of tumor recurrence in ovarian serous carcinoma and to have a causal role in the development of paclitaxel resistance. Therefore, we selected NACC1 for validation in an independent cohort. On the basis of fluorescence in situ hybridization, we found that 35 (20%) of 175 high-grade serous carcinomas had an increased DNA copy number at the NACC1 locus, and those amplified cases were associated with early disease recurrence within 6 months (P0.013). A significantly high level of NAC1 protein expression based on immunohistochemistry was detected in amplified tumors as compared with non-amplified tumors (P0.005). In summary, our data suggest that amplification at the ch19p13.2 NACC1 locus, leading to NAC1 overexpression, is one of the molecular genetic alterations associated with early tumor recurrence in ovarian cancer.

KW - gene amplification

KW - ovarian cancer

KW - serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=79955622235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955622235&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2010.230

DO - 10.1038/modpathol.2010.230

M3 - Article

VL - 24

SP - 638

EP - 645

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -